Atara Biotherapeutics Inc. Common Stock (ATRA)

About ATRA

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseas…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

10

Website

www.atarabio.com/

Fundamentals

1-day range

$8.9$9.21

Market cap

$77.04M

P/E (trailing)

—

P/E (forward)

5.88

EPS (trailing)

$-1.18

Dividend yield

—

Beta

0.22

Avg. volume

70.2K

Forecasts

3 analyst ratings

Atara Biotherapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ATRA

  Atara Biotherapeutics Inc. Common Stock

  $9.16

  ▼ 0.97%
  Market cap $77.04MP/E —
  $3.92$19.15
• CGTX

  Cognition Therapeutics Inc. Common Stock

  $1.03

  ▼ 3.30%
  Market cap $79.79MP/E —
  $0.5501$3.1
• GNTA

  Genenta Science S.p.A. American Depositary Shares

  $1

  ▼ 1.96%
  Market cap $67.99MP/E —
  $0.55$10
• IMA

  ImageneBio Inc. Common Stock

  $5.34

  ▲ 0.19%
  Market cap $63.61MP/E —
  $3.94$13.98
• XTNT

  Xtant Medical Holdings Inc. Common Stock

  $0.4055

  ▲ 22.88%
  Market cap $61.72MP/E 23.84
  $0.2702$0.95
• PTHS

  Pelthos Therapeutics Inc. Common Stock

  $24.46

  ▼ 2.16%
  Market cap $93.29MP/E —
  $18.19$37.5
• KLRS

  Kalaris Therapeutics Inc. Common Stock

  $4.03

  ▼ 1.71%
  Market cap $96.36MP/E —
  $3.03$11.88

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate
  benzinga · 8/12/2026
• Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate
  Benzinga · 8/12/2026

• AnhCo Nguyen · August 17, 2026 · Sale

  5.1K @ $8.08
• Redmile Group, LLC · July 22, 2026 · Option Exercise

  55.4K
• Redmile Group, LLC · July 22, 2026 · Option Exercise

  38.7K
• Redmile Group, LLC · July 22, 2026 · Option Exercise

  101.1K
• Redmile Group, LLC · July 22, 2026 · Tax Withholding

  60
• Redmile Group, LLC · July 22, 2026 · Option Exercise

  195.2K
• Brian N. Cherry · June 11, 2026 · Grant

  24.0K
• Gregory Austin Ciongoli · June 9, 2026 · Grant

  12.0K
• Matthew K. Fust · June 9, 2026 · Grant

  12.0K
• William K. Heiden · June 9, 2026 · Grant

  12.0K
• AnhCo Nguyen · May 18, 2026 · Sale

  5.2K @ $9.13
• Yanina Grant-Huerta · May 18, 2026 · Sale

  2.4K @ $9.13
• EcoR1 Capital, LLC · May 7, 2026 · Buy

  507.4K @ $9.35
• James Huang · May 7, 2026 · Sale

  313.4K @ $10.1
• James Huang · March 17, 2026 · Option Exercise

  259.2K @ $0.0001

Institutional Ownership

March 31, 2026

Total shares held

2.53M

Total value held

$11.34M

Institutional holders

31